WO2002020731A2 - Regulation de l'enzyme humaine du type proteine disulfide isomerase - Google Patents

Regulation de l'enzyme humaine du type proteine disulfide isomerase Download PDF

Info

Publication number
WO2002020731A2
WO2002020731A2 PCT/EP2001/010125 EP0110125W WO0220731A2 WO 2002020731 A2 WO2002020731 A2 WO 2002020731A2 EP 0110125 W EP0110125 W EP 0110125W WO 0220731 A2 WO0220731 A2 WO 0220731A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
disulfide isomerase
polypeptide
protein disulfide
enzyme
Prior art date
Application number
PCT/EP2001/010125
Other languages
English (en)
Other versions
WO2002020731A3 (fr
Inventor
Yonghong Xiao
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Priority to AU2001289864A priority Critical patent/AU2001289864A1/en
Publication of WO2002020731A2 publication Critical patent/WO2002020731A2/fr
Publication of WO2002020731A3 publication Critical patent/WO2002020731A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Definitions

  • the invention relates to the area of regulation of human protein disulfide isomerase- like enzyme to provide therapeutic effects.
  • Cells contain a number of proteins known as molecular chaperones or foldases.
  • U.S. Patent 6,001,632. These molecules catalyze the folding of newly synthesized proteins, prevent aggregation and improper glycosylation, and remove denatured proteins. Although they do not become part of the final structure, they are important in the assembly of proteins or their subunits into larger, more complex structures. In the absence of chaperones and foldases, misfolded proteins are quickly degraded by intracellular proteases.
  • Foldases such as protein disulfide isomerase (PDI) are specialized enzymes which carry out rate-limiting covalent steps in protein folding. These enzymes are most abundant in cells actively synthesizing secreted proteins which are major components of the ER lumen. Tasanen et al, J. Biol. Chem. 267, 11513-19, 1992) and may constitute 1-2% of eukaryotic cellular proteins. Although incubation of reduced unfolded proteins in buffers with defined ratios of oxidized and reduced thiols can lead to native conformation, the rate of folding is slow and the attainment of native conformation decreases proportionately to the size and number of cysteines in the protein.
  • PDI protein disulfide isomerase
  • PDI in the eukaryotic ER is much more efficient in carrying out the enzymatic pairing and oxidation of cysteines.
  • Human PDI is a resident endoplasmic reticulum protein which mediates the formation of disulfide bonds in recently synthesized proteins. Chen et al, Br. J. Haematol. 90, 425-31, 1995. PDI has recently been localized additional sites. Catalytically active PDI also has been localized to the plasma membrane of mammalian cells and platelets. PDI is also released from activated and inactivated platelets. Id. PDI catalyzes the reversible formation and isomerization of disulfide bonds, thus promoting correct protein folding. Id.; Essex et al, Blood 86, 2168- 73,1995.
  • the activity of PDI is extremely concentration-dependent under certain conditions.
  • PDI can promote the misfolding and aggregation of its substrates.
  • PDI When PDI is present at high concentrations relative to substrate, it acts a chaperone, increasing the yield of properly folded protein, and inhibiting substrate aggregation.
  • PDI In contrast when PDI is present at substoichionaetric concentrations relative to substrate, it facilitates aggregation and inhibits proper protein folding.
  • Sideraki & Gilbert
  • PDI plays an important role in platelet responses. PDI has been shown to mediate platelet aggregation and secretion. PDI is further postulated to promote wound healing by facilitating the proper folding of proteins important for tissue remodeling.
  • TGF ⁇ l potent antiproliferative Tissue Growth Factor ⁇ l
  • TGF ⁇ l -resistant tumor cells do not alter their pattern of PDI expression after treatment with TGF ⁇ l.
  • PDI is postulated to interfere with TGF ⁇ l activity by either altering the folding of the TGF ⁇ l receptor or the TGF ⁇ l molecule itself. Sipes et al, Cell Growth & Diff. 1, 241-46, 1990. Because of the importance of PDI in a variety of cellular processes, there is a need in the art to identify additional related molecules which can be regulated to provide therapeutic effects.
  • amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:2,
  • amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:29,
  • Yet another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation.
  • a test compound is contacted with a protein disulfide isomerase-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of:
  • amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:2 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:29,
  • Binding between the test compound and the protein disulfide isomerase-like enzyme polypeptide is detected.
  • a test compound which binds to the protein disulfide isomerase-like enzyme polypeptide is thereby identified as a potential agent for decreasing extracellular matrix degradation.
  • the agent can work by decreasing the activity of the protein disulfide isomerase-like enzyme.
  • Another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation.
  • a test compound is contacted with a polynucleotide encoding a protein disulfide isomerase-like enzyme polypeptide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:
  • nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO:l,
  • nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO:28,
  • a test compound which binds to the polynucleotide is identified as a potential agent for decreasing extracellular matrix degradation.
  • the agent can work by decreasing the amount of the protein disulfide isomerase-like enzyme through interacting with the protein disulfide isomerase-like enzyme mRNA.
  • Another embodiment of the invention is a method of screening for agents which regulate extracellular matrix degradation.
  • a test compound is contacted with a protein disulfide isomerase-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of:
  • amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:2,
  • amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:29,
  • a protein disulfide isomerase-like enzyme activity of the polypeptide is detected.
  • a test compound which increases protein disulfide isomerase-like enzyme activity of the polypeptide relative to protein disulfide isomerase-like enzyme activity in the absence of the test compound is thereby identified as a potential agent for increasing extracellular matrix degradation.
  • a test compound which decreases protein disulfide isomerase-like enzyme activity of the polypeptide relative to protein disulfide isomerase-like enzyme activity in the absence of the test compound is thereby identified as a potential agent for decreasing extracellular matrix degradation.
  • Even another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation.
  • a test compound is contacted with a protein disulfide isomerase-like enzyme product of a polynucleotide which comprises a nucleotide sequence selected from the group consisting of:
  • nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO:l,
  • nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO:28,
  • Binding of the test compound to the protein disulfide isomerase-like enzyme product is detected.
  • a test compound which binds to the protein disulfide isomerase-like enzyme product is thereby identified as a potential agent for decreasing extracellular matrix degradation.
  • Still another embodiment of the invention is a method of reducing extracellular matrix degradation.
  • a cell is contacted with a reagent which specifically binds to a polynucleotide encoding a protein disulfide isomerase-like enzyme polypeptide or the product encoded by the polynucleotide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:
  • nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO:l,
  • nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO:28, the nucleotide sequence shown in SEQ ID NO:l;
  • Protein disulfide isomerase-like enzyme activity in the cell is thereby decreased.
  • the invention thus provides a human protein disulfide isomerase-like enzyme which can be used to identify test compounds which may act, for example, as agonists or antagonists at the enzyme's active site.
  • Human protein disulfide isomerase-like enzyme and fragments thereof also are useful in raising specific antibodies which can block the enzyme and effectively reduce its activity.
  • Fig. 1 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:l).
  • Fig. 2 shows the amino acid sequence deduced from the DNA-sequence of Fig.l (SEQ ID NO:2).
  • Fig. 3 shows the amino acid sequence of the protein identified by SwissProt
  • Fig. 4 shows the amino acid sequence of pfam/hmm/thiored (SEQ ID NO:4).
  • Fig. 5 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:5).
  • Fig. 6 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:6).
  • Fig. 7 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:7).
  • Fig. 8 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:8).
  • Fig. 9 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:9).
  • Fig. 10 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO: 10).
  • Fig. 11 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO: 11).
  • Fig. 12 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO: 12).
  • Fig. 13 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO: 13).
  • Fig. 14 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO: 14).
  • Fig. 15 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO: 15).
  • Fig. 16 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:16).
  • Fig. 17 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO: 17).
  • Fig. 18 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO: 18).
  • Fig. 19 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO: 19).
  • Fig. 20 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:20).
  • Fig. 21 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:21).
  • Fig. 22 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:22).
  • Fig. 23 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:23).
  • Fig. 24 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:24).
  • Fig. 25 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:25).
  • Fig. 26 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:26).
  • Fig. 27 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:27).
  • Fig. 28 shows the BLASTP alignment of 59_PROTEIN (SEQ ID NO:2) against swiss
  • Fig. 29 shows the BLOCKS search results.
  • Fig. 30 shows the HMMPFAM - alignment of 59_PROTEIN (SEQ ID NO:2) against ⁇ fam
  • Fig. 31 shows the DNA-sequence encoding a protein disulfide isomerase-like enzyme polypeptide (SEQ ID NO:28).
  • Fig. 32 shows the amino acid sequence deduced from the DNA-sequence of
  • Fig. 31 (SEQ ID NO:29).
  • Fig. 33 shows the BLASTP alignment of 59_short_TRl against swiss/P30101/ER60_HUMAN.
  • Fig. 34 shows the HMMPFAM alignment of 59_short_TRl against pfam/hmm/thiored.
  • Fig. 35 shows the expression profile of protein disulfide isomerase-like protein mRNA in whole body tissues.
  • Fig. 36 shows the expression profile of protein disulfide isomerase-like protein mRNA in blood and lung tissues.
  • the invention relates to an isolated polynucleotide encoding a protein disulfide isomerase-like enzyme polypeptide and being selected from the group consisting of:
  • amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:2 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:29,
  • Human protein disulfide isomerase-like enzyme comprises the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:29, as encoded by the coding sequence shown in SEQ ID NO:l and
  • Human protein disulfide isomerase-like enzyme is 32% identical over a 131 amino acid overlap to the protein identified by SwissProt Accession No. Q10057 (SEQ ID NO:3) and amiotated as "PUTATIVE PROTEIN DISULFIDE ISOMERASE
  • the human protein disulfide isomerase-like enzyme of the invention is expected to be useful for the same p poses as previously identified protein disulfide isomerase enzymes.
  • protein disulfide isomerase is found on the surface of platelets and is released upon platelet activation and mediates platelet aggregation and secretion. Because platelets are present and become activated when and where vascular injury occurs, platelet protein disulfide isomerase and, therefore, human protein disulfide isomerase-like enzyme, may play a role in the various hemostatic and tissue remodeling processes in which platelets (hence blood coagulation) are involved. Protein disulfide isomerase also has a regulatory effect on the surface protein thiol status of B cells.
  • protein disulfide isomerase may play a crucial role in SH-mediated protection and dmg resistance in malignant B lymphocytes.
  • Protein disulfide isomerase mRNA levels co ⁇ elate inversely with sensitivity to the growth-inhibitory effects of TGF ⁇ 1, and protein disulfide isomerase down-regulation occurs in some TGF ⁇ -sensitive cells, but not in a human pancreatic carcinoma cell line which is insensitive to the growth-inhibitory effects of TGF ⁇ 1.
  • human protein disulfide isomerase-like enzyme is expressed mainly in tumor and other highly proliferative tissues (i.e., tissues with a rich blood supply), it is a potential target for diseases therapeutic sensitivity/resistance involving blood clotting, vascular wall repair and formation, as well as tissue remodeling.
  • Human protein disulfide isomerase-like enzyme therefore can be used in therapeutic methods to treat disorders such as hematological disorders, cardiovascular disorders, and cancer.
  • Human protein disulfide isomerase-like enzyme also can be used to screen for human protein disulfide isomerase-like enzyme agonists and antagonists.
  • Protein disulfide isomerase-like polypeptides according to the invention comprise at least 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, or 390 contiguous amino acids selected from the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:29 or a biologically active variant thereof, as defined below.
  • a protein disulfide isomerase-like polypeptide of the invention therefore can be a portion of a protein disulfide isomerase-like enzyme, a full-length protein disulfide isomerase-like enzyme, or a fusion protein comprising all or a portion of a protein disulfide isomerase-like enzyme.
  • Protein disulfide isomerase-like polypeptide variants which are biologically active, i.e., retain a protein disulfide isomerase-like activity, also are protein disulfide isomerase-like polypeptides.
  • naturally or non-naturally occurring protein disulfide isomerase-like polypeptide variants have amino acid sequences which are at least about 50, 55, 60, 65, or 70, preferably about 75, 80, 85, 90, 96, 96, or 98% identical to the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:29 or a fragment thereof.
  • Percent identity between a putative protein disulfide isomerase- like polypeptide variant and an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:29 is determined using the Blast2 alignment program (Blosum62, Expect 10, standard genetic codes). Variations in percent identity can be due, for example, to amino acid substitutions, insertions, or deletions. Amino acid substitutions are defined as one for one amino acid replacements. They are conservative in nature when the substituted amino acid has similar stractural and/or chemical properties. Examples of conservative replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.
  • Amino acid insertions or deletions are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity of a protein disulfide isomerase-like polypeptide can be found using computer programs well known in the art, such as DNASTAR software. Whether an amino acid change results in a biologically active protein disulfide isomerase-like polypeptide can readily be determined by assaying for protein disulfide isomerase-like activity, as described for example, in Sideraki &
  • Fusion proteins are useful for generating antibodies against protein disulfide isomerase-like polypeptide amino acid sequences and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with portions of a protein disulfide isomerase-like polypeptide. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.
  • a protein disulfide isomerase-like polypeptide fusion protein comprises two polypeptide segments fused together by means of a peptide bond.
  • the first polypeptide segment comprises at least 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300,
  • the first polypeptide segment also can comprise full-length protein disulfide isomerase-like enzyme protein.
  • the second polypeptide segment can be a full-length protein or a protein fragment.
  • Proteins commonly used in fusion protein construction include ⁇ -galactosidase, ⁇ -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT).
  • GFP green fluorescent protein
  • BFP blue fluorescent protein
  • GST glutathione-S-transferase
  • luciferase luciferase
  • HRRP horseradish peroxidase
  • CAT chloramphenicol acetyltransferase
  • epitope tags are used in fusion protein constructions, including histidine
  • His tags
  • FLAG tags FLAG tags
  • influenza hemagglutinin (HA) tags influenza hemagglutinin (HA) tags
  • Myc tags influenza hemagglutinin (HA) tags
  • Myc tags influenza hemagglutinin (HA) tags
  • Myc tags influenza hemagglutinin (HA) tags
  • Myc tags influenza hemagglutinin (HA) tags
  • Myc tags influenza hemagglutinin (HA) tags
  • VSV-G tags VSV-G tags
  • Trx thioredoxin
  • Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and he ⁇ es simplex virus (HSV) BP16 protein fusions.
  • MBP maltose binding protein
  • S-tag S-tag
  • Lex a DNA binding domain (DBD) fusions Lex a DNA binding domain
  • a fusion protein also can be engineered to contain a cleavage site located between the protein disulfide isomerase-like polypeptide-encoding sequence and the heterologous protein sequence, so that the protein disulfide isomerase-like polypeptide can be cleaved and purified away from the heterologous moiety.
  • a fusion protein can be synthesized chemically, as is known in the art.
  • a fusion protein is produced by covalently linking two polypeptide segments or by standard procedures in the art of molecular biology.
  • Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which comprises coding sequences selected from SEQ ID NO:l or SEQ ID NO:28 in proper reading frame with nucleotides encoding the second polypeptide segment and expressing the DNA construct in a host cell, as is known in the art.
  • kits for constructing fusion proteins are available from companies such as Promega Co ⁇ oration (Madison, Wl), Stratagene (La Jolla, CA), CLONTECH (Mountain View, CA), Santa Cruz Biotechnology (Santa Cruz, CA), MBL International Co ⁇ oration (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal,
  • Species homologs of human protein disulfide isomerase-like polypeptide can be obtained using protein disulfide isomerase-like polypeptide polynucleotides (described below) to make suitable probes or primers for screening cDNA expression libraries from other species, such as mice, monkeys, or yeast, identifying cDNAs which encode homologs of protein disulfide isomerase-like polypeptide, and expressing the cDNAs as is known in the art.
  • a protein disulfide isomerase-like polynucleotide can be single- or double-stranded and comprises a coding sequence or the complement of a coding sequence for a protein disulfide isomerase-like polypeptide.
  • a coding sequence for human protein disulfide isomerase-like enzyme is shown in SEQ ID NO:l and SEQ ID NO:28. This coding sequence is found within the larger genomic sequence shown in SEQ ID NO:5.
  • nucleotide sequences encoding human protein disulfide isomerase-like polypeptides as well as homologous nucleotide sequences which are at least about 50, 55, 60, 65, 70, preferably about 75, 90, 96, or 98% identical to the nucleotide sequence shown in SEQ ID NO:l or SEQ ID NO:28 also are protein disulfide isomerase-like polynucleotides. Percent sequence identity between the sequences of two polynucleotides is determined using computer programs such as ALIGN which employ the FASTA algorithm, using an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2.
  • cDNA Complementary DNA molecules, species homologs, and variants of protein disulfide isomerase-like polynucleotides which encode biologically active protein disulfide isomerase-like polypeptides also are protein disulfide isomerase-like polynucleotides. Identification of Polynucleotide Variants and Homologs
  • variants and homologs of the protein disulfide isomerase-like polynucleotides described above also are protein disulfide isomerase-like polynucleotides.
  • homologous protein disulfide isomerase-like polynucleotide sequences can be identified by hybridization of candidate polynucleotides to known protein disulfide isomerase-like polynucleotides under stringent conditions, as is known in the art. For example, using the following wash conditions: 2X SSC (0.3 M NaCI, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2X SSC, 0.1% SDS, 50 EC once, 30 minutes; then 2X SSC, room temperature twice,
  • each homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.
  • Species homologs of the protein disulfide isomerase-like polynucleotides disclosed herein also can be identified by making suitable probes or primers and screening cDNA expression libraries from other species, such as mice, monkeys, or yeast.
  • Human variants of protein disulfide isomerase-like polynucleotides can be identified, for example, by screening human cDNA expression libraries. It is well known that the T m of a double-stranded DNA decreases by 1-1.5°C with every 1% decrease in homology (Bonner et al, J. Mol Biol 81, 123 (1973).
  • Variants of human protein disulfide isomerase-like polynucleotides or protein disulfide isomerase-like polynucleotides of other species can therefore be identified by hybridizing a putative homologous protein disulfide isomerase-like polynucleotide with a polynucleotide having a nucleotide sequence of SEQ ID NO:l or SEQ ID NO:28 or the complement thereof to form a test hybrid.
  • the melting temperature of the test hybrid is compared with the melting temperature of a hybrid comprising polynucleotides having perfectly complementary nucleotide sequences, and the number or percent of basepair mismatches within the test hybrid is calculated.
  • Nucleotide sequences which hybridize to protein disulfide isomerase-like polynucleotides or their complements following stringent hybridization and/or wash conditions also are protein disulfide isomerase-like polynucleotides.
  • Stringent wash conditions are well known and understood in the art and are disclosed, for example, in Sambrook et al, MOLECULAR CLONING: A LABORATORY MANUAL, 2d ed., 1989, at pages 9.50-9.51.
  • T m of a hybrid between a protein disulfide isomerase-like polynucleotide having a nucleotide sequence shown in SEQ ID NO:l or SEQ ID NO:28 or the complement thereof and a polynucleotide sequence which is at least about 50, 55, 60, 65, 70, preferably about 75, 90, 96, or 98%) identical to one of those nucleotide sequences can be calculated, for example, using the equation of Bolton and McCarthy, Proc. Natl Acad. Sci. U.S.A. 48, 1390
  • Stringent wash conditions include, for example, 4X SSC at 65°C, or 50% formamide,
  • a naturally occurring protein disulfide isomerase-like polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids.
  • Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated protein disulfide isomerase-like polynucleotides.
  • restriction enzymes and probes can be used to isolate polynucleotide fragments which comprises protein disulfide isomerase-like enzyme nucleotide sequences.
  • Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.
  • Protein disulfide isomerase-like enzyme cDNA molecules can be made with standard molecular biology techniques, using protein disulfide isomerase-like enzyme mRNA as a template. Protein disulfide isomerase-like enzyme cDNA molecules can thereafter be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook et al. (1989). An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or cDNA as a template.
  • synthetic chemistry techniques can be used to synthesizes protein disulfide isomerase-like polynucleotides.
  • the degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode a protein disulfide isomerase-like polypeptide having, for example, an amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:29 or a biologically active variant thereof.
  • the partial nucleotide sequence disclosed herein can be used to identify the conesponding full length gene from which they were derived.
  • the partial sequence can be nick-translated or end-labeled with 32 P using polynucleotide kinase using labeling methods known to those with skill in the art (BASIC METHODS IN MOLECULAR BIOLOGY, Davis et al, eds., Elsevier Press, N.Y., 1986).
  • a lambda library prepared from human tissue can be directly screened with the labeled sequences of interest or the library can be converted en masse to pBluescript (Stratagene Cloning Systems, La Jolla, Calif. 92037) to facilitate bacterial colony screening (see Sambrook et al, MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press (1989, pg. 1.20).
  • filters with bacterial colonies containing the library in pBluescript or bacterial lawns containing lambda plaques are denatured, and the DNA is fixed to the filters.
  • the filters are hybridized with the labeled probe using hybridization conditions described by Davis et al, 1986.
  • the partial sequences, cloned into lambda or pBluescript, can be used as positive controls to assess background binding and to adjust the hybridization and washing stringencies necessary for accurate clone identification.
  • the resulting autoradio- grams are compared to duplicate plates of colonies or plaques; each exposed spot corresponds to a positive colony or plaque.
  • the colonies or plaques are selected, expanded and the DNA is isolated from the colonies for further analysis and sequencing.
  • Positive cDNA clones are analyzed to determine the amount of additional sequence they contain using PCR with one primer from the partial sequence and the other primer from the vector.
  • Clones with a larger vector-insert PCR product than the original partial sequence are analyzed by restriction digestion and DNA sequencing to determine whether they contain an insert of the same size or similar as the mRNA size determined from Northern blot Analysis.
  • the complete sequence of the clones can be determined , for example after exonuclease III digestion (McCombie et al, Methods 3, 33-40, 1991).
  • a series of deletion clones are generated, each of which is sequenced.
  • the resulting overlapping sequences are assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a highly accurate final sequence.
  • Various PCR-based methods can be used to extend the nucleic acid sequences disclosed herein to detect upstream sequences such as promoters and regulatory elements.
  • restriction site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, PCR Methods Applic. 2, 318322, 1993). Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.
  • Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region (Triglia et al, Nucleic Acids Res. 16, 8186, 1988).
  • Primers can be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Madison, Mima.), to be 2230 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C.
  • the method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.
  • capture PCR involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom et al, PCR Methods Applic. 1, 111119, 1991).
  • multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.
  • Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' nontranscribed regulatory regions.
  • capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products.
  • capillary sequencing can employ fiowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera.
  • Output/light intensity can be converted to electrical signal using appropriate software (e.g. GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled.
  • Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.
  • Protein disulfide isomerase-like polypeptides can be obtained, for example, by purification from human cells, by expression of protein disulfide isomerase-like polynucleotides, or by direct chemical synthesis. Protein Purification
  • Protein disulfide isomerase-like polypeptides can be purified from any cell which expresses the enzyme, including host cells which have been fransfected with protein disulfide isomerase-like enzyme expression constructs.
  • a purified protein disulfide isomerase-like polypeptide is separated from other compounds which normally associate with the protein disulfide isomerase-like polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.
  • a preparation of purified protein disulfide isomerase-like polypeptides is at least 80% pure; preferably, the preparations are 90%, 95%, or 99% pure. Purity of the preparations can be assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis.
  • the polynucleotide can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.
  • Methods which are well known to those skilled in the art can be used to constmct expression vectors containing sequences encoding protein disulfide isomerase-like polypeptides and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described, for example, in Sambrook et ⁇ l. (1989) and in Ausubel et al, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1989.
  • a variety of expression vector/host systems can be utilized to contain and express sequences encoding a protein disulfide isomerase-like polypeptide.
  • microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors
  • yeast transformed with yeast expression vectors insect cell systems infected with virus expression vectors (e.g., baculoviras)
  • plant cell systems transformed with virus expression vectors e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus,
  • TMV TMV
  • bacterial expression vectors e.g., Ti or pBR322 plasmids
  • animal cell systems e.g., TMV, TMV, TMV, TMV, TMV, or with bacterial expression vectors (e.g., Ti or pBR322 plasmids), or animal cell systems.
  • control elements or regulatory sequences are those nontranslated regions of the vector enhancers, promoters, 5' and 3' untranslated regions which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORTl plasmid (Life Technologies) and the like can be used. The baculoviras polyhedrin promoter can be used in insect cells.
  • Promoters or enhancers derived from the genomes of plant cells e.g., heat shock, RUBISCO, and storage protein genes
  • plant viruses e.g., viral promoters or leader sequences
  • promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding a protein disulfide isomerase-like polypeptide, vectors based on S V40 or EB V can be used with an appropriate selectable marker.
  • a number of expression vectors can be selected depending upon the use intended for the protein disulfide isomerase-like polypeptide. For example, when a large quantity of a protein disulfide isomerase-like polypeptide is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional E. coli cloning and expression vectors such as BLUESCRTPT (Stratagene).
  • a sequence encoding the protein disulfide isomerase-like polypeptide can be ligated into the vector in frame with sequences for the amino terminal Met and the subsequent 7 residues of ⁇ - galactosidase so that a hybrid protein is produced.
  • pIN vectors Van Heeke & Schuster, J Biol Chem. 264, 55035509, 1989
  • pGEX vectors Promega, Madison, Wis.
  • GST glutathione S-transferase
  • fusion proteins are soluble and can easily be purified from lysed cells by adso ⁇ tion to glutathione agarose beads followed by elution in the presence of free glutathione.
  • Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.
  • yeast Saccharomyces cerevisiae a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used.
  • constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH.
  • sequences encoding protein disulfide isomerase-like polypeptides can be driven by any of a number of promoters.
  • viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV (Takamatsu, EMBO J. 6, 307311, 1987).
  • plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used (Coruzzi et al, EMBO J. 3, 16711680, 1984; Broglie et al, Science 224, 838843, 1984; Winter et al, Results Pr obi Cell Differ. 77, 85105, 1991).
  • These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection.
  • An insect system also can be used to express a protein disulfide isomerase-like polypeptide.
  • Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae.
  • Sequences encoding protein disulfide isomerase-like polypeptides can be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of protein disulfide isomerase-like polypeptides will render the polyhedrin gene inactive and produce recombinant vims lacking coat protein.
  • the recombinant viruses can then be used to infect S. frugiperda cells or Trichoplusia larvae in which protein disulfide isomerase-like polypeptides can be expressed (Engelhard et al, Proc. Nat. Acad. Sci. 91, 32243227, 1994).
  • a number of viral-based expression systems can be used to express protein disulfide isomerase-like polypeptides in mammalian host cells.
  • sequences encoding protein disulfide isomerase-like polypeptides can be ligated into an adenovims transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a nonessential El or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing a protein disulfide isomerase-like polypeptide in infected host cells (Logan & Shenk, Proc. Natl. Acad. Sci. 81, 36553659, 1984).
  • transcription enhancers such as the Rous sarcoma virus (RS V) enhancer, can be used to increase expression in mammalian host cells.
  • RS V Rous sarcoma virus
  • HACs Human artificial chromosomes
  • 6M to 10M are constructed and delivered to cells via conventional delivery methods (e.g., liposomes, polycationic amino polymers, or vesicles).
  • Specific initiation signals also can be used to achieve more efficient translation of sequences encoding protein disulfide isomerase-like polypeptides. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding a protein disulfide isomerase-like polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used (see Scharf et al, Results Probl Cell Differ. 20, 125162, 1994).
  • a host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein disulfide isomerase-like polypeptide in the desired fashion.
  • modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation.
  • Posttranslational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function.
  • Different host cells which have specific cellular machinery and characteristic mechanisms for Post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.
  • ATCC American Type Culture Collection
  • Stable expression is prefe ⁇ ed for long-tenn, high-yield production of recombinant proteins.
  • cell lines which stably express protein disulfide isomerase- like polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 12 days in an enriched medium before they are switched to a selective medium. The pu ⁇ ose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced protein disulfide isomerase-like enzyme sequences. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, ANIMAL CELL CULTURE, R.I. Freshney, ed., 1986.
  • he ⁇ es simplex virus thymidine kinase (Wigler et al, Cell 11, 22332, 1977) and adenine phosphoribosyltransferase (Lowy et al, Cell 22, 81723, 1980) genes which can be employed in t/ " or aprf cells, respectively.
  • antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection.
  • dhfr confers resistance to methotrexate (Wigler et al, Proc. Nat Acad. Sci.
  • npt confers resistance to the aminoglycosides, neomycin and G418 (Colbere-Garapin et al, J. Mol. Biol. 150, 114, 1981), and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Mu ⁇ ay, 1992, supra). Additional selectable genes have been described. For example, trpB allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartinan & Mulligan, Proc. Natl. Acad. Sci. 85, 804751, 1988).
  • Visible markers such as anthocyanins, ⁇ -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system
  • marker gene expression suggests that the protein disulfide isomerase-like polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a protein disulfide isomerase- like polypeptide is inserted within a marker gene sequence, transformed cells containing sequences which encode a protein disulfide isomerase-like polypeptide can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a protein disulfide isomerase-like polypeptide under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the protein disulfide isomerase-like polynucleotide.
  • host cells which contain a protein disulfide isomerase-like polynucleotide and which express a protein disulfide isomerase-like polypeptide can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein.
  • the presence of a polynucleotide sequence encoding a protein disulfide isomerase-like polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of poly- nucleotides encoding a protein disulfide isomerase-like polypeptide.
  • Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a protein disulfide isomerase-like polypeptide to detect transformants which contain a protein disulfide isomerase-like polynucleotide.
  • a variety of protocols for detecting and measuring the expression of a protein disulfide isomerase-like polypeptide, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme- linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS).
  • ELISA enzyme- linked immunosorbent assay
  • RIA radioimmunoassay
  • FACS fluorescence activated cell sorting
  • a two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on a protein disulfide isomerase-like polypeptide can be used, or a competitive binding assay can be employed.
  • Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding protein disulfide isomerase-like polypeptides include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.
  • sequences encoding a protein disulfide isomerase-like polypeptide can be cloned into a vector for the production of an mRNA probe.
  • RNA probes are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like. Expression and Purification of Polypeptides
  • Host cells transformed with nucleotide sequences encoding a protein disulfide isomerase-like polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture.
  • the polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used.
  • expression vectors containing polynucleotides which encode protein disulfide isomerase-like polypeptides can be designed to contain signal sequences which direct secretion of soluble protein disulfide isomerase-like polypeptides through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound protein disulfide isomerase-like polypeptide.
  • purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system
  • cleavable linker sequences such as those specific for Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the protein disulfide isomerase-like polypeptide also can be used to facilitate purification.
  • One such expression vector provides for expression of a fusion protein containing a protein disulfide isomerase-like polypeptide and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilized metal ion affinity chromatography, as described in Porath et al, Prot. Exp. Purif.
  • enterokinase cleavage site provides a means for purifying the protein disulfide isomerase-like polypeptide from the fusion protein.
  • Vectors which contain fusion proteins are disclosed in Kroll et al, DNA Cell Biol. 12, 441453, 1993. Chemical Synthesis
  • Sequences encoding a protein disulfide isomerase-like polypeptide can be synthesized, in whole or in part, using chemical methods well known in the art (see
  • a protein disulfide isomerase-like polypeptide itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques (Merrifield, J Am. Chem. Soc. 85, 21492154, 1963; Roberge et al, Science 269,
  • Protein synthesis can be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431 A Peptide Synthesizer (Perkin Elmer).
  • fragments of protein disulfide isomerase-like polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.
  • the newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES, WH Freeman and Co., New York, N.Y., 1983).
  • the composition of a synthetic protein disulfide isomerase-like polypeptide can be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, supra). Additionally, any portion of the amino acid sequence of the protein disulfide isomerase-like polypeptide can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.
  • codons prefe ⁇ ed by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.
  • nucleotide sequences disclosed herein can be engineered using methods generally known in the art to alter protein disulfide isomerase-like polypeptide-encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product.
  • DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences.
  • site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.
  • Antibody as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab,
  • F(ab') , and Fv which are capable of binding an epitope of a protein disulfide isomerase-like polypeptide.
  • a protein disulfide isomerase-like polypeptide typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope.
  • epitopes which involve non-contiguous amino acids may require more, e.g., at least 15, 25, or 50 amino acids.
  • An antibody which specifically binds to an epitope of a protein disulfide isomerase- like polypeptide can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radioimmuno assays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art.
  • immunochemical assays such as Western blots, ELISAs, radioimmuno assays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art.
  • Various immunoassays can be used to identify antibodies having the desired specificity.
  • Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the immunogen.
  • an antibody which specifically binds to a protein disulfide isomerase-like polypeptide provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay.
  • antibodies which specifically bind to protein disulfide isomerase- like polypeptides do not detect other proteins in immunochemical assays and can immunoprecipitate a protein disulfide isomerase-like polypeptide from solution.
  • Protein disulfide isomerase-like polypeptides can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies.
  • a protein disulfide isomerase-like polypeptide can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin.
  • a carrier protein such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin.
  • various adjuvants can be used to increase the immunological response.
  • adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (e.g., aluminum hydroxide), and surface active substances (e.g.
  • BCG Bacilli Calmette-Gueri ⁇
  • Corynebacterium parvum are especially useful.
  • Monoclonal antibodies which specifically bind to a protein disulfide isomerase-like polypeptide can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human B cell hybridoma technique, and the EBV hybridoma technique (Kohler et al, Nature 256, 495497, 1985; Kozbor et al, J. Immunol. Methods 81, 3142, 1985; Cote et al, Proc. Natl. Acad. Sci. 80, 20262030, 1983; Cole et al, Mol. Cell Biol. 62, 109120, 1984).
  • chimeric antibodies the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison et al, Proc. Natl. Acad. Sci. 81, 68516855, 1984; Neuberger et al, Nature 312, 604608, 1984; Takeda et al, Nature 314, 452454, 1985).
  • Monoclonal and other antibodies also can be "humanized” to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues.
  • rodent antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grating of entire complementarity determining regions.
  • humanized antibodies can be produced using recombinant methods, as described in GB2188638B.
  • Antibodies which specifically bind to a protein disulfide isomerase- like polypeptide can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. Patent 5,565,332.
  • single chain antibodies can be adapted using methods known in the art to produce single chain antibodies which specifically bind to protein disulfide isomerase-like polypeptides.
  • Antibodies with related specificity, but of distinct idiotypic composition can be generated by chain shuffling from random combinatorial immunoglobin libraries (Burton, Proc. Natl. Acad. Sci. 88, 1112023, 1991).
  • Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template (Thirion et al, 1996, Eur. J. Cancer Prev. 5, 507-11).
  • Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught, for example, in Coloma & Morrison, 1997, Nat. Biotechnol 15, 159-63. Construction of bivalent, bispecific single-chain antibodies is taught in
  • a nucleotide sequence encoding a single-chain antibody can be constracted using manual or automated nucleotide synthesis, cloned into an expression constract using standard recombinant DNA methods, and introduced into a cell to express the coding sequence, as described below.
  • single-chain antibodies can be produced directly using, for example, filamentous phage technology (Verhaar et al, 1995, Int. J. Cancer 61, 497-501; Nicholls et al, 1993, J Immunol. Meth. 165, 81-91).
  • Antibodies which specifically bind to protein disulfide isomerase-like polypeptides also can be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi et al, Proc. Natl. Acad. Sci. 86, 38333837, 1989; Winter et al, Nature 349, 293299, 1991).
  • chimeric antibodies can be constracted as disclosed in WO 93/03151.
  • Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.
  • Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which a protein disulfide isomerase-like polypeptide is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.
  • Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation.
  • an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used.
  • Antisense oligonucleotide molecules can be provided in a DNA constract and introduced into a cell as described above to decrease the level of protein disulfide isomerase-like enzyme gene products in the cell.
  • Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. See Brown, Meth. Mol. Biol. 20, 18, 1994; Sonveaux, Meth. Mol. Biol. 26, 1-72, 1994; Uhlmarm et al,
  • Modifications of protein disulfide isomerase-like enzyme gene expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of the protein disulfide isomerase-like enzyme gene.
  • Oligonucleotides derived from the transcription initiation site are preferred.
  • inhibition can be achieved using "triple helix" base-pairing methodology.
  • Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons.
  • Therapeutic advances using triplex DNA have been described in the literature (e.g., Gee et al, in Huber & Can, MOLECULAR AND IMMUNOLOGIC APPROACHES, Futura Publishing Co., Mt. Kisco, N.Y., 1994).
  • An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to rib ⁇ somes. Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a protein disulfide isomerase-like polynucleotide.
  • Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a protein disulfide isomerase-like polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent protein disulfide isomerase-like enzyme nucleotides, can provide sufficient targeting specificity for protein disulfide isomerase-like enzyme mRNA.
  • each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length.
  • Non-complementary intervening sequences are preferably 1, 2,
  • Antisense oligonucleotides can be modified without affecting their ability to hybridize to a protein disulfide isomerase-like polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule. For example, inte ⁇ aucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose.
  • Modified bases and/or sugars such as arabinose instead of ribose, or a 3', 5' substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide.
  • modified oligonucleotides can be prepared by methods well known in the art. See, e.g., Agrawal et al, Trends Biotechnol. 10, 152158, 1992;
  • Ribozymes are RNA molecules with catalytic activity. See, e.g., Cech, Science 236, 15321539; 1987; Cech, Ann. Rev. Biochem. 59, 543568; 1990, Cech, Curr. Opin. Struct. Biol. 2, 605609; 1992, Couture & Stinchcomb, Trends Genet. 12, 510515,
  • Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (e.g., Haseloff et al, U.S. Patent 5,641,673).
  • the mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences.
  • the coding sequence of a protein disulfide isomerase-like polynucleotide can be used to generate ribozymes which will specifically bind to mRNA transcribed from the protein disulfide isomerase-like polynucleotide.
  • Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art (see Haseloff et al. Nature 334, 585591, 1988).
  • the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme.
  • the hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target (see, for example, Gerlach et al, EP 321,201).
  • RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary stractural features which may render the target inoperable. Suitability of candidate protein disulfide isomerase-like enzyme RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target.
  • the hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.
  • Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct.
  • DNA constract into cells in which it is desired to decrease protein disulfide isomerase-like enzyme expression.
  • the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art.
  • a ribozyme-encoding DNA constract can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells.
  • ribozymes can be engineered so that ribozyme expression will occur in response to factors which induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.
  • genes whose products interact with human protein disulfide isomerase-like enzyme may represent genes which are differentially expressed in disorders including, but not limited to, cancer, diabetes, and obesity. Further, such genes may represent genes which are differentially regulated in response to mampulations relevant to the progression or treatment of such diseases. Additionally, such genes may have a temporally modulated expression, increased or decreased at different stages of tissue or organism development. A differentially expressed gene may also have its expression modulated under control versus experimental conditions. In addition, the human protein disulfide isomerase-like gene or gene product may itself be tested for differential expression.
  • the degree to which expression differs in a normal versus a diseased state need only be large enough to be visualized via standard characterization techniques such as differential display techniques.
  • standard characterization techniques such as differential display techniques.
  • Other such standard characterization techniques by which expression differences may be visualized include but are not limited to, quantitative RT (reverse transcriptase), PCR, and Northern analysis.
  • RNA samples are obtained from tissues of experimental subjects and from corresponding tissues of control subjects. Any RNA isolation technique which does not select against the isolation of mRNA may be utilized for the purification of such RNA samples. See, for example, Ausubel et al, ed. dislike CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, Inc. New York, 1987-1993. Large numbers of tissue samples may readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski, U.S. Patent 4,843,155.
  • Transcripts within the collected RNA samples which represent RNA produced by differentially expressed genes are identified by methods well known to those of skill in the art. They include, for example, differential screening (Tedder et al, Proc. Natl. Acad. Sci. U.S.A. 85, 208-12, 1988), subfractive hybridization (Hedrick et al,
  • the differential expression information may itself suggest relevant methods for the treatment of disorders involving the human protein disulfide isomerase-like enzyme.
  • treatment may include a modulation of expression of the differentially expressed genes and/or the gene encoding the human protein disulfide isomerase-like enzyme.
  • the differential expression information may indicate whether the expression or activity of the differentially expressed gene or gene product or the human protein disulfide isomerase-like gene or gene product are up-regulated or down-regulated.
  • the invention provides assays for screening test compounds which bind to or modulate the activity of a protein disulfide isomerase-like polypeptide or a protein disulfide isomerase-like polynucleotide.
  • a test compound preferably binds to a protein disulfide isomerase-like polypeptide or polynucleotide. More preferably, a test compound decreases or increases protein disulfide isomerase-like activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the test compound.
  • Test compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity.
  • the compounds can be naturally occurring or designed in the laboratory. They can be isolated from microorganisms, animals, or plants, and can be produced recombinantly, or synthesized by chemical methods known in the art. If desired, test compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the "one-bead one-compound” library method, and synthetic library methods using affinity chromatography selection.
  • the biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of compounds. See Lam, Anticancer Drug Des. 12, 145, 1997.
  • Test compounds can be screened for the ability to bind to protein disulfide isomerase-like polypeptides or polynucleotides or to affect protein disulfide isomerase-like enzyme activity or protein disulfide isomerase-like enzyme gene expression using high throughput screening.
  • high throughput screening many discrete compounds can be tested in parallel so that large numbers of test compounds can be quickly screened.
  • the most widely established techniques utilize 96-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 50 to 500 ⁇ l.
  • many instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the 96-well format.
  • free format assays or assays that have no physical barrier between samples, can be used.
  • an assay using pigment cells (melanocytes) in a simple homogeneous assay for combinatorial peptide libraries is described by Jayawickreme et al, Proc. Natl. Acad. Sci. U.S.A. 19, 161418 (1994).
  • the cells are placed under agarose in petii dishes, then beads that carry combinatorial compounds are placed on the surface of the agarose.
  • the combinatorial compounds are partially released the compounds from the beads. Active compounds can be visualized as dark pigment areas because, as the compounds diffuse locally into the gel matrix, the active compounds cause the cells to change colors.
  • Chelsky "Strategies for Screening Combinatorial Libraries: Novel and Traditional Approaches," reported at the First Annual Conference of The Society for Biomolecular Screening in Philadelphia, Pa. (Nov. 710, 1995).
  • Chelsky placed a simple homogenous enzyme assay for carbonic anhydrase inside an agarose gel such that the enzyme in the gel would cause a color change throughout the gel.
  • beads carrying combinatorial compounds via a photolinker were placed inside the gel and the compounds were partially released by UV light. Compounds that inhibited the enzyme were observed as local zones of inhibition having less color change.
  • test samples are placed in a porous matrix.
  • One or more assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support.
  • a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support.
  • the test compound is preferably a small molecule which binds to and occupies, for example, the ATP/GTP binding site of the enzyme or the active site of the protein disulfide isomerase-like polypeptide, such that normal biological activity is prevented.
  • small molecules include, but are not limited to, small peptides or peptide-like molecules.
  • either the test compound or the protein disulfide isomerase-like polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
  • a detectable label such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
  • Detection of a test compound which is bound to the protein disulfide isomerase-like polypeptide can then be accomplished, for example, by direct counting of radioemmission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product.
  • binding of a test compound to a protein disulfide isomerase-like polypeptide can be determined without labeling either of the interactants.
  • a microphysiometer can be used to detect binding of a test compound with a protein disulfide isomerase-like polypeptide.
  • a microphysiometer e.g., Cyto- sensorJ
  • a microphysiometer is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and a protein disulfide isomerase-like polypeptide (McConnell et al, Science 257, 19061912, 1992).
  • Determining the ability of a test compound to bind to a protein disulfide isomerase- like polypeptide also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) (Sjolander & Urbaniczky, Anal Chem. 63, 23382345, 1991, and Szabo et al, Curr. Opin. Struct. Biol. 5, 699705, 1995).
  • BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcoreTM). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.
  • a protein disulfide isomerase-like polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent 5,283,317; Zervos et al, Cell 72, 223232, 1993; Madura et al, J. Biol.
  • the two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains.
  • the assay utilizes two different DNA constructs.
  • polynucleotide encoding a protein disulfide isomerase-like polypeptide can be fused to a poly- nucleotide encoding the DNA binding domain of a known transcription factor (e.g.,
  • a DNA sequence that encodes an unidentified protein (“prey” or “sample”) can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait” and the “prey” proteins are able to interact in vivo to form an protein-dependent complex, the DNA-BINDING and activation domains of the transcription factor are brought into close proximity.
  • reporter gene e.g., LacZ
  • a reporter gene e.g., LacZ
  • Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with the protein disulfide isomerase-like polypeptide. It may be desirable to immobilize either the protein disulfide isomerase-like polypeptide (or polynucleotide) or the test compound to facilitate separation of bound from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay.
  • either the protein disulfide isomerase- like polypeptide (or polynucleotide) or the test compound can be bound to a solid support.
  • suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads).
  • any method known in the art can be used to attach the protein disulfide isomerase-like polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive abso ⁇ tion, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support.
  • Test compounds are preferably bound to the solid support in an a ⁇ ay, so that the location of individual test compounds can be tracked. Binding of a test compound to a protein disulfide isomerase-like polypeptide (or polynucleotide) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.
  • the protein disulfide isomerase-like polypeptide is a fusion protein comprising a domain that allows the protein disulfide isomerase-like polypeptide to be bound to a solid support.
  • glutathione S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the nonadsorbed protein disulfide isomerase-like polypeptide; the mixture is then incubated under conditions conducive to complex formation (e.g. , at physiological conditions for salt and pH).
  • Binding of the interactants can be determined either directly or indirectly, as described above.
  • the complexes can be dissociated from the solid support before binding is determined.
  • Other techniques for immobilizing proteins or polynucleotides on a solid support also can be used in the screening assays of the invention. For example, either a protein disulfide isomerase-like polypeptide (or polynucleotide) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin.
  • Biotinylated protein disulfide isomerase-like polypeptides or polynucleotides
  • test compounds can be prepared from biotir ⁇ NHS(Nhydroxysuccinimide) using teclmiques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, 111.) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
  • antibodies which specifically bind to a protein disulfide isomerase-like polypeptide, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the ATP/GTP binding site or the active site of the protein disulfide isomerase-like polypeptide, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.
  • Methods for detecting such complexes include immunodetection of complexes using antibodies which specifically bind to the protein disulfide isomerase-like polypeptide or test compound, enzyme-linked assays which rely on detecting an activity of the protein disulfide isomerase-like polypeptide, and SDS gel electrophoresis under non-reducing conditions.
  • Any cell which comprises a protein disulfide isomerase-like polypeptide or polynucleotide can be used in a cell-based assay system.
  • a protein disulfide isomerase-like polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Binding of the test compound to a protein disulfide isomerase-like polypeptide or polynucleotide is determined as described above.
  • Test compounds can be tested for the ability to increase or decrease the protein disulfide isomerase-like activity of a human protein disulfide isomerase-like polypeptide.
  • Protein disulfide isomerase-like activity can be measured, for example, as described in the specific examples, below, and in Sideraki & Gilbert, 2000, Essex et al, 1995, or Chen et al, 1992.
  • Enzyme assays can be carried out after contacting either a purified protein disulfide isomerase-like polypeptide, a cell membrane preparation, or an intact cell with a test compound.
  • a test compound which decreases a transketolase activity of a protein disulfide isomerase-like polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for decreasing protein disulfide isomerase- like enzyme activity.
  • a test compound which increases a transketolase activity of a human protein disulfide isomerase-like polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for increasing human protein disulfide isomerase-like enzyme activity.
  • test compounds which increase or decrease protein disulfide isomerase-like enzyme gene expression are identified.
  • a protein disulfide isomerase- like polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of the protein disulfide isomerase-like polynucleotide is determined.
  • the level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound.
  • the test compound can then be identified as a modulator of expression based on this comparison.
  • test compound when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression.
  • test compound when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.
  • the level of protein disulfide isomerase-like enzyme mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or polypeptide. Either qualitative or quantitative methods can be used.
  • the presence of polypeptide products of a protein disulfide isomerase-like polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry.
  • polypeptide synthesis can be determined in vivo, in a cell culture, or in an in vitro translation system by detecting inco ⁇ oration of labeled amino acids into a protein disulfide isomerase-like polypeptide.
  • Such screening can be carried out either in a cell-free assay system or in an intact cell.
  • Any cell which expresses a protein disulfide isomerase-like polynucleotide can be used in a cell-based assay system.
  • the protein disulfide isomerase-like polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above.
  • Either a primary culture or an established cell line, such as CHO or human embryonic kidney 293 cells, can be used.
  • compositions of the invention can comprise, for example, a protein disulfide isomerase-like polypeptide, protein disulfide isomerase-like polynucleotide, ribozymes or antisense oligonucleotides, antibodies which specifically bind to a protein disulfide isomerase-like polypeptide, or mimetics, agonists, antagonists, or inhibitors of a protein disulfide isomerase-like polypeptide activity.
  • compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.
  • agent such as stabilizing compound
  • the compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.
  • compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means.
  • Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
  • compositions for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, maitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxy- propylmethylcellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen.
  • disintegrating or solubilizing agents can be added, such as the cross-linked polyvinyl py ⁇ olidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
  • Dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.
  • Push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.
  • Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers.
  • the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
  • compositions suitable for parenteral administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline.
  • Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • suspensions of the active compounds can be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Non-lipid polycationic amino polymers also can be used for delivery.
  • the suspension also can contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • compositions of the present invention can be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
  • the pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.
  • the prefe ⁇ ed preparation can be a lyophilized powder which can contain any or all of the following: 150 mM histidine, 0.1 %2% sucrose, and 27% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.
  • compositions After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.
  • PDI has been associated with failure of potent anti-proliferative proteins such as TGF ⁇ l to inhibit proliferation of cancer cells. It is postulated that PDI acts by altering the binding of either the protein or its receptor.
  • Cancer is a disease fundamentally caused by oncogenic cellular transformation. There are several hallmarks of transformed cells that distinguish them from their normal counte ⁇ arts and underlie the pathophysiology of cancer. These include uncontrolled cellular proliferation, unresponsiveness to normal death inducing signals (immortalization), increased cellular motility and invasiveness, increased ability to recruit blood supply through induction of new blood vessel formation (angiogenesis), genetic instability, and dysregulated gene expression. Various combinations of these abe ⁇ ant physiologies, along with the acquisition of drug- resistance frequently lead to an intractable disease state in which organ failure and patient death ultimately ensue.
  • Genes playing important roles in any of the physiological processes outlined above can be characterized as cancer targets.
  • Genes or gene fragments identified through genomics can readily be expressed in one or more heterologous expression systems to produce functional recombinant proteins. These proteins are characterized in vitro for their biochemical properties and then used as tools in high-throughput molecular screening programs to identify chemical modulators of their biochemical activities.
  • Agonists and or antagonists of target protein activity can be identified in this manner and subsequently tested in cellular and in vivo disease models for anticancer activity. Optimization of lead compounds with iterative testing in biological models and detailed pharmacokinetic and toxicological analyses form the basis for drug development and subsequent testing in humans.
  • Human protein disulfide isomerase-like enzyme also can be regulated to treat hematological disorders and atherosclerosis. Atherosclerosis is associated with abnormally high level of PDI. Therefore, blocking the activity of human protein disulfide isomerase-like enzyme would be a viable approach to treating or preventing atherosclerosis. Human protein disulfide isomerase-like enzyme also can be regulated to treat other cardiovascular disorders. Cardiovascular diseases include the following disorders of the heart and the vascular system: congestive heart failure, myocardial infarction, ischemic diseases of the heart, all kinds of atrial and ventricular arrhythmias, hypertensive vascular diseases and peripheral vascular diseases.
  • Heart failure is defined as a pathophysiologic state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failure such as high-output and low-output, acute and chronic, right-sided or left-sided, systolic or diastolic, independent of the underlying cause.
  • MI Myocardial infarction
  • Ischemic diseases are conditions in which the coronary flow is restricted resulting in an perfusion which is inadequate to meet the myocardial requirement for oxygen.
  • This group of diseases include stable angina, unstable angina and asymptomatic ischemia.
  • Arrhythmias include all forms of atrial and ventricular tachya ⁇ hythmias (atrial tachycardia, atrial flutter, atrial fibrillation, atrio-ventricular reentrant tachycardia, preexcitation syndrome, ventricular tachycardia, ventricular flutter, ventricular fibrillation) as well as bradycardic forms of arrhythmias.
  • Hypertensive vascular diseases include primary as well as all kinds of secondary arterial hypertension (renal, endocrine, neurogenic, others). The genes may be used as drug targets for the treatment of hypertension as well as for the prevention of all complications.
  • Peripheral vascular diseases are defined as vascular diseases in which arterial and/or venous flow is reduced resulting in an imbalance between blood supply and tissue oxygen demand. It includes chronic peripheral arterial occlusive disease (PAOD), acute arterial thrombosis and embolism, inflammatory vascular disorders, Raynaud's phenomenon and venous disorders.
  • PAOD peripheral arterial occlusive disease
  • acute arterial thrombosis and embolism inflammatory vascular disorders
  • Raynaud's phenomenon and venous disorders.
  • PDI is postulated to play a role in wound healing, because PDI is released from activated platelets. PDI may promote tissue remodeling and arrest of bleeding by reduction or isomerization of protein bonds. By enhancing the expression of human protein disulfide isomerase-like enzyme, it may be possible to increase the levels of properly folded proteins that are important in facilitating would healing.
  • This invention further pertains to the use of novel agents identified by the screening assays described above. Accordingly, it is within the scope of this invention to use a test compound identified as described herein in an appropriate animal model.
  • an agent identified as described herein e.g., a modulating agent, an antisense nucleic acid molecule, a specific antibody, ribozyme, or a human protein disulfide isomerase-like polypeptide binding molecule
  • an agent identified as described herein can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent.
  • an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent.
  • this invention pertains to uses of novel agents identified by the above described screening assays for treatments as described herein.
  • a reagent which affects human protein disulfide isomerase-like enzyme activity can be administered to a human cell, either in vitro or in vivo, to reduce human protein disulfide isomerase-like enzyme activity.
  • the reagent preferably binds to an expression product of a human protein disulfide isomerase-like enzyme gene. If the expression product is a protein, the reagent is preferably an antibody.
  • an antibody can be added to a preparation of stem cells which have been removed from the body. The cells can then be replaced in the same or another human body, with or without clonal propagation, as is known in the art.
  • the reagent is delivered using a liposome.
  • the liposome is stable in the animal into which it has been administered for at least about
  • a liposome comprises a lipid composition that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human.
  • the lipid composition of the liposome is capable of targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph nodes, and skin.
  • a liposome useful in the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell.
  • the transfection efficiency of a liposome is about
  • a liposome is between about 100 and 500 nm, more preferably between about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter.
  • Suitable liposomes for use in the present invention include those liposomes standardly used in, for example, gene delivery methods known to those of skill in the art. More prefe ⁇ ed liposomes include liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol.
  • a liposome comprises a compound capable of targeting the liposome to a particular cell type, such as a cell-specific ligand exposed on the outer surface of the liposome.
  • Complexing a liposome with a reagent such as an antisense oligonucleotide or ribozyme can be achieved using methods which are standard in the art (see, for example, U.S. Patent 5,705,151).
  • polynucleotide is combined with about 8 nmol of liposomes, more preferably from about 0.5 ⁇ g to. about 5 ⁇ g of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0 ⁇ g of polynucleotides is combined with about 8 nmol liposomes.
  • antibodies can be delivered to specific tissues in vivo using receptor-mediated targeted delivery.
  • Receptor-mediated DNA delivery techniques are taught in, for example, Findeis et al. Trends in Biotechnol 11, 202-05 (1993);
  • a therapeutically effective dose refers to that amount of active ingredient which increases or decreases human protein disulfide isomerase- like enzyme activity relative to the human protein disulfide isomerase-like enzyme activity which occurs in the absence of the therapeutically effective dose.
  • the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs.
  • the animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • Therapeutic efficacy and toxicity e.g., ED 50 (the dose therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals.
  • the dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD 50 /ED 5 Q.
  • compositions which exhibit large therapeutic indices are preferred.
  • the data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use.
  • the dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
  • the exact dosage will be detennined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect.
  • Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drag combination(s), reaction sensitivities, and tolerance/response to therapy.
  • Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.
  • Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration.
  • Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
  • polynucleotides encoding the antibody can be constracted and introduced into a cell either ex vivo or in vivo using well- established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, elecfroporation, "gene gun,” and DEAE- or calcium phosphate-mediated transfection.
  • Effective in vivo dosages of an antibody are in the range of about 5 ⁇ g to about 50 ⁇ g/kg, about 50 ⁇ g to about 5 mg/kg, about 100 ⁇ g to about 500 ⁇ g/kg of patient body weight, and about 200 to about 250 ⁇ g/kg of patient body weight.
  • effective in vivo dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1 ⁇ g to about 2 mg, about 5 ⁇ g to about 500 ⁇ g, and about 20 ⁇ g to about 100 ⁇ g of DNA.
  • the reagent is preferably an antisense oligonucleotide or a ribozyme.
  • Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above.
  • a reagent reduces expression of a human protein disulfide isomerase-like enzyme gene or the activity of a human protein disulfide isomerase-like polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent.
  • the effectiveness of the mechanism chosen to decrease the level of expression of a human protein disulfide isomerase-like enzyme gene or the activity of a human protein disulfide isomerase-like polypeptide can be assessed using methods well known in the art, such as hybridization of nucleotide probes to human protein disulfide isomerase-like enzyme-specific mRNA, quantitative RT-PCR, immuno logic detection of a human protein disulfide isomerase-like polypeptide, or measurement of human protein disulfide isomerase- like enzyme activity.
  • any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents.
  • Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles.
  • the combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
  • any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.
  • Human protein disulfide isomerase-like enzyme also can be used in diagnostic assays for detecting diseases and abnormalities or susceptibility to diseases and abnormalities related to the presence of mutations in the nucleic acid sequences which encode the enzyme. For example, differences can be determined between the cDNA or genomic sequence encoding protein disulfide isomerase-like enzyme in individuals afflicted with a disease and in normal individuals. If a mutation is observed in some or all of the afflicted individuals but not in normal individuals, then the mutation is likely to be the causative agent of the disease.
  • Sequence differences between a reference gene and a gene having mutations can be revealed by the direct DNA sequencing method.
  • cloned DNA segments can be employed as probes to detect specific DNA segments.
  • the sensitivity of this method is greatly enhanced when combined with PCR.
  • a sequencing primer can be used with a double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is perforaied by conventional procedures using radiolabeled nucleotides or by automatic sequencing procedures using fluorescent tags.
  • DNA sequence differences can be carried out by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized, for example, by high resolution gel electrophoresis. DNA fragments of different sequences can be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (see, e.g. , Myers et al, Science 230, 1242, 1985). Sequence changes at specific locations can also be revealed by nuclease protection assays, such as RNase and S 1 protection or the chemical cleavage method (e.g., Cotton et al, Proc. Natl. Acad. Sci. USA 85,
  • the detection of a specific DNA sequence can be performed by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes and Southern blotting of genomic DNA.
  • direct methods such as gel electrophoresis and DNA sequencing, mutations can also be detected by in situ analysis.
  • Altered levels of a protein disulfide isomerase-like enzyme also can be detected in various tissues.
  • Assays used to detect levels of the receptor polypeptides in a body sample, such as blood or a tissue biopsy, derived from a host are well known to those of skill in the art and include radioimmunoassays, competitive binding assays,
  • the polynucleotide of SEQ ID NO:l or SEQ ID NO:28 is inserted into the expression vector pCEV4 and the expression vector pCEV4-protein disulfide isomerase-like enzyme polypeptide obtained is fransfected into human embryonic kidney 293 cells. From these cells extracts are obtained and the protein disulfide isomerase-like enzyme activity is measured by it's ability to refold scrambled Rnase A, which in turn will regain its ability to cleave highly polymerized yeast RNA (Lambert and Freedman, 1983).
  • the cell extract (2,0 ⁇ g/ml) is dissolved in 100 mM sodium phosphate, pH 7,5, 2 mM glutathione, and 0,2 mM reduced glutathione.
  • the reaction is started by the addition of 200 ⁇ g of scrambled Rnase A (Hillson et al, 1984).
  • Protein disulfide isomerase-like enzyme activity is determined in the presence of recombinant calretioulin, purified N-, P-, and C-domains of calreticulin, and in the presence of cardiac calsequestrin.
  • the proteins are used in 1:1 molar ratio.
  • the A260/A280 ratio over a period of 60 min is measured as indicative of the extent of cleavage of yeast RNA by refolded Rnase A. It is shown that the polypeptide of SEQ ID NO:2 and SEQ ID NO:29 has a protein disulfide isomerase- like enzyme activity.
  • the Pichia pastoris expression vector pPICZB (Invitrogen, San Diego, CA) is used to produce large quantities of recombinant human protein disulfide isomerase-like polypeptides in yeast.
  • the protein disulfide isomerase-like enzyme-encoding DNA sequence is derived from SEQ ID NO:l or SEQ ID NO:28.
  • the DNA sequence is modified by well known methods in such a way that it contains at its 5' end an initiation codon and at its 3' end an enterokinase cleavage site, a His6 reporter tag and a termination codon.
  • the yeast is cultivated under usual conditions in 5 liter shake flasks and the recombinantly produced protein isolated from the culture by affinity chromatography (NiNTAResin) in the presence of 8 M urea.
  • the bound polypeptide is eluted with buffer, pH 3.5, and neutralized. Separation of the polypeptide from the His6 reporter tag is accomplished by site-specific proteolysis using enterokinase (Invitrogen, San
  • Human protein disulfide isomerase-like enzyme activity is measured by renaturation of inactivated RNase. Briefly, RNase is inactivated by formation of randomly mismatched or scrambled disulfide bonds. Deactivated RNase renatures slowly in the presence of a thiol reagent. Human protein disulfide isomerase-like enzyme accelerates the renaturation process. The amount of renatured RNase is measured by its ability to digest RNA. RNA digestion is measured by an increase in absorbance at 260 nm. A test compound which decreases protein disulfide isomerase-like activity relative to control levels by at least 20% is identified as a protein disulfide isomerase-like enzyme inhibitor.
  • Protein disulfide isomerase-like polypeptides comprising a glutathione-S-transferase protein and absorbed onto glutathione-derivatized wells of 96-well microtiter plates are contacted with test compounds from a small molecule library at pH 7.0 in a physiological buffer solution.
  • Protein disulfide isomerase-like polypeptides comprise the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:29.
  • the test compounds comprise a fluorescent tag. The samples are incubated for 5 minutes to one hour. Control samples are incubated in the absence of a test compound.
  • the buffer solution containing the test compounds is washed from the wells. Binding of a test compound to a protein disulfide isomerase-like polypeptide is detected by fluorescence measurements of the contents of the wells. A test compound which increases the fluorescence in a well by at least 15% relative to fluorescence of a well in which a test compound is not incubated is identified as a compound which binds to a protein disulfide isomerase-like polypeptide.
  • test compound which decreases protein disulfide isomerase-like enzyme gene expression
  • a test compound is administered to a culture of human cells fransfected with a protein disulfide isomerase-like enzyme expression constract and incubated at 37°C for 10 to 45 minutes.
  • a culture of the same type of cells which have not been fransfected is incubated for the same time without the test compound to provide a negative control.
  • RNA is isolated from the two cultures as described in Chirgwin et al, Biochem. 18, 5294-99, 1979).
  • Northern blots are prepared using 20 to 30 Fg total RNA and hybridized with a 32 P-labeled protein disulfide isomerase-like enzyme-specific probe at 65° C in Express-hyb (CLONTECH).
  • the probe comprises at least 11 contiguous nucleotides selected from the complement of SEQ ID NO:l or SEQ ID NO:28.
  • a test compound which decreases the protein disulfide isomerase-like enzyme-specific signal relative to the signal obtained in the absence of the test compound is identified as an inhibitor of protein disulfide isomerase-like enzyme gene expression.
  • a human pancreatic carcinoma line which does not downregulate the expression of human protein disulfide isomerase-like enzyme in response to TGF ⁇ l and which is resistant to the anti-proliferative effects of TGF ⁇ l is used for testing.
  • Cells are cultured in RPMI-1640 with 10-15% fetal calf serum at a concentration of 10,000 cells per milliliter in a volume of 0.5 ml and kept at 37 °C in a 95% air/5%CO 2 atmosphere.
  • Phosphorothioate oligoribonucleotides are synthesized on an Applied Biosystems
  • ID NO:28 is used as the test oligonucleotide.
  • another (random) sequence is used: 5'-TCA ACT GAC TAG ATG TAG ATG GAC-3'.
  • oligonucleotides are ethanol-precipitated twice, dried, and suspended in phosphate buffered saline at the desired concentration. Purity of the oligonucleotides is tested by capillary gel electrophoresis and ion exchange HPLC. The purified oligonucleotides are added to the culture medium at a concentration of 10 ⁇ M once per day for seven days.
  • test oligonucleotide for seven days together with TGF ⁇ l results in significantly reduced expression of human protein disulfide isomerase-like enzyme as determined by Western blotting. This effect is not observed with the control oligonucleotide.
  • the number of cells in the cultures is counted using an automatic cell counter. The number of cells in cultures treated with the test oligonucleotide (expressed as 100%) is compared with the number of cells in cultures treated with the control oligonucleotide. The number of cells in cultures treated with the test oligonucleotide is not more than 30% of control, indicating that the inhibition of human protein disulfide isomerase-like enzyme has an anti-proliferative effect on cancer cells.
  • Expression profiling is based on a quantitative polymerase chain reaction (PCR) analysis, also called kinetic analysis, first described in Higuchi et al, 1992 and Higuchi et al, 1993.
  • PCR polymerase chain reaction
  • the principle is that at any given cycle within the exponential phase of PCR, the amount of product is proportional to the initial number of template copies.
  • mRNA messenger RNA
  • cDNA DNA copy
  • quantitative RT-PCR quantitative reverse transcription-polymerase chain reaction
  • RNA from different human tissues was performed to investigate the tissue distribution of human protein disulfide isomerase-like enzyme, Sphingosine kinase-like mRNA. In most cases, 25 . ⁇ g of total RNA from various tissues (including Human Total RNA Panel I-V, Clontech Laboratories, Palo
  • Alto, CA, USA was used as a template to synthsize first-strand cDNA using the SUPERSCRIPTTM First-Strand Synthesis System for RT-PCR (Life Technologies, Rockville , MD, USA).
  • First-strand cDNA synthesis was carried out according to the manufacturer's protocol using oligo (dT) to hybridize to the 3' poly A tails of mRNA and prime the synthesis reaction.
  • oligo (dT) to hybridize to the 3' poly A tails of mRNA and prime the synthesis reaction.
  • Approximately 10 ng of the first-strand cDNA was then used as template in a polymerase chain reaction.
  • 10 ng of commercially available cDNAs (Human Immune System MTC Panel and Human Blood Fractions MTC Panel, Clontech Laboratories, Palo Alto, CA, USA) were used as template in a polymerase chain reaction.
  • the polymerase chain reaction was performed in a LightCycler (Roche Molecular Biochemicals, Indianapolis, IN, USA), in the presence of the DNA-binding fluorescent dye SYBR Green I which binds to the minor groove of the DNA double helix, produced only when double-stranded DNA is successfully synthesized in the reaction. Upon binding to double-stranded DNA, SYBR Green I emits light that can be quantitatively measured by the LightCycler machine.
  • the polymerase chain reaction was carried out using oligonucleotide primers LBRI059-L2:
  • GGACACATTCACTGTGGCAAGG and LBRI059-R2 TGGAAGCAGGG TCTGAGTGATG
  • G3PDH glyceraldehyde-3-phosphatase
  • HPRT hypoxanthine guanine phophoribosyl transferase
  • beta-actin beta-actin
  • PBGD po ⁇ hobilinogen deaminase
  • the level of housekeeping gene expression is considered to be relatively constant for all tissues and therefore can be used as a gauge to approximate relative numbers of cells per ⁇ g of total RNA used in the cDNA synthesis step. Except for the use of a slightly different set of housekeeping genes and the use of the
  • RNA The calculated copy numbers for each gene, derived from comparison with simultaneously reacted standards of known concentrations, were recorded and the mean number of copies of each gene in all tissue samples was determined. Then for each tissue sample, the expression of each housekeeping gene relative to the mean was calculated, and the average of these values over the five housekeeping genes was found. A normalization factor for each tissue was then calculated by dividing the final value for one of the tissues arbitrarily selected as a standard by the conesponding value for each of the tissues. To normalize an experimentally obtained value for the expression of a particular gene in a tissue sample, the obtained value was multiplied by the normalization factor for the tissue tested.
  • Human protein disulfide isomerase-like enzyme is a widely distributed, highly expressed molecule, indicating that its function may be fundamental to common activities of a wide variety of cell types. As a member of the protein disulfide isomerase family, this function would most likely be in helping different proteins assume their proper three-dimensional configuration.
  • human protein disulfide isomerase-like enzyme Although the expression of human protein disulfide isomerase-like enzyme is high in most tissues, its expression in the lung is 1.5 to 2 times that seen in any other tissue. This suggests that the lung may produce a comparatively large amount of specific protein types, for example proteins lining or secreted into the lung airways, that require human protein disulfide isomerase-like enzyme activity to allow them to fold or combine with other molecules before assuming an active conformation. Regulating the activity of human protein disulfide isomerase-like enzyme in cells or tissues such as lung that produce human protein disulfide isomerase-like enzyme - activity-dependent proteins, therefore, may be beneficial in pathogenic states where ove ⁇ roduction or unde ⁇ roduction of active protein leads to disease.
  • Table 1 Material used to determine the expression in whole body tissues.
  • Table 2 Material used to determine the expression in the blood and lung tissues.

Abstract

L'invention concerne des réactifs qui permettent de réguler l'enzyme humaine du type protéine disulfide isomérase, et des réactifs qui se lient à des produits de gènes de l'enzyme humaine du type protéine disulfide isomérase, et qui peuvent jouer un rôle dans la prévention, l'amélioration ou la correction de dysfonctionnements ou de troubles qui comprennent mais ne se limitent pas au cancer, au diabète, et à l'obésité.
PCT/EP2001/010125 2000-09-08 2001-09-03 Regulation de l'enzyme humaine du type proteine disulfide isomerase WO2002020731A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001289864A AU2001289864A1 (en) 2000-09-08 2001-09-03 Regulation of human protein disulfide isomerase-like enzyme

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23129700P 2000-09-08 2000-09-08
US60/231,297 2000-09-08

Publications (2)

Publication Number Publication Date
WO2002020731A2 true WO2002020731A2 (fr) 2002-03-14
WO2002020731A3 WO2002020731A3 (fr) 2002-07-25

Family

ID=22868615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010125 WO2002020731A2 (fr) 2000-09-08 2001-09-03 Regulation de l'enzyme humaine du type proteine disulfide isomerase

Country Status (2)

Country Link
AU (1) AU2001289864A1 (fr)
WO (1) WO2002020731A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079238A2 (fr) * 2001-04-02 2002-10-10 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteine bisulfure isomerase et proteines homologues transporteuses d'abc impliquees dans la regulation de l'hemostase energetique
WO2003086461A2 (fr) * 2002-04-15 2003-10-23 Proteosys Ag Utilisation de substances pour traiter des tumeurs
US7238513B2 (en) 2003-02-28 2007-07-03 University Of Utah Research Foundation Nucleic acid sequences encoding Conus protein disulfide isomerase
WO2010004214A1 (fr) * 2008-07-10 2010-01-14 bioMérieux Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
US8361731B2 (en) 2007-07-19 2013-01-29 Biomerieux Ezrin assay method for the in vitro diagnosis of colorectal cancer
US8367362B2 (en) 2007-07-19 2013-02-05 Biomerieux Aminoacylase 1 assay method for the in vitro diagnosis of colorectal cancer
US8445211B2 (en) 2007-07-19 2013-05-21 Biomerieux I-Plastin assay method for the in vitro diagnosis of colorectal cancer
US8735078B2 (en) 2007-07-19 2014-05-27 Biomerieux Apolipoprotein AII assay method for the in vitro diagnosis of colorectal cancer
US9726670B2 (en) 2007-07-19 2017-08-08 Biomerieux Method for the assay of liver fatty acid binding protein, ACE and CA 19-9 for the in vitro diagnosis of colorectal cancer
US9891223B2 (en) 2007-07-19 2018-02-13 Biomerieux Method of assaying leukocyte elastase inhibitor for the in vitro diagnosis of colorectal cancer
US10591482B2 (en) 2007-07-19 2020-03-17 Biomerieux Method of assaying Apolipoprotein AI for the in vitro diagnosis of colorectal cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001632A (en) * 1996-05-15 1999-12-14 Incyte Pharmaceuticals, Inc. Human protein disulfide isomerase
WO2001012790A2 (fr) * 1999-08-17 2001-02-22 Incyte Genomics, Inc. Proteines d'isomerase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001632A (en) * 1996-05-15 1999-12-14 Incyte Pharmaceuticals, Inc. Human protein disulfide isomerase
WO2001012790A2 (fr) * 1999-08-17 2001-02-22 Incyte Genomics, Inc. Proteines d'isomerase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_EST [Online] EMBL; 13 March 1999 (1999-03-13) OTTENWALD ET AL.: "EST" retrieved from EBI, accession no. HSM006372 Database accession no. AL048830 XP002198789 *
DATABASE EM_EST [Online] EMBL; 8 June 2000 (2000-06-08) HEGDE ET AL.: "EST" retrieved from EBI, accession no. AW959209 Database accession no. AW959209 XP002198788 *
DATABASE EM_HUM [Online] EMBL; 15 March 1999 (1999-03-15) ANDERSSON ET AL.: "Homo sapiens clone 25100 mRNA sequence, complete cds." retrieved from EBI, accession no. AF131780 Database accession no. AF131780 XP002198786 -& DATABASE SWALL [Online] 1 May 1999 (1999-05-01) NDERSSON ET AL.: "Hypothetical 37.7 kDa protein" retrieved from EBI, accession no. O95887 Database accession no. O95887 XP002198787 & ANAL BIOCHEM, vol. 236, 1996, pages 107-113, XP000857646 & GENOME RES, vol. 7, no. 4, 1997, pages 353-358, XP000867830 *
DATABASE EM_HUM [Online] EMBL; 15 May 2001 (2001-05-15) ISOGAI ET AL.: "Homo sapiens cDNA FLJ14558 fis ...." retrieved from EBI, accession no. AK027464 Database accession no. AK027464 XP002198790 -& DATABASE SWALL [Online] 1 December 2001 (2001-12-01) ISOGAI ET AL.: "cDNA FLJ14558 fis ...." retrieved from EBI, accession no. Q96K53 Database accession no. Q96K53 XP002198791 *
TASANEN ET AL.: "Promoter of the gene for the multifunctional protein disulfide isomerase polypeptide" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 16, 5 June 1992 (1992-06-05), pages 11513-11519, XP002198785 cited in the application *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079238A3 (fr) * 2001-04-02 2003-09-04 Develogen Ag Proteine bisulfure isomerase et proteines homologues transporteuses d'abc impliquees dans la regulation de l'hemostase energetique
WO2002079238A2 (fr) * 2001-04-02 2002-10-10 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteine bisulfure isomerase et proteines homologues transporteuses d'abc impliquees dans la regulation de l'hemostase energetique
US7759068B2 (en) 2002-04-15 2010-07-20 Proteosys Ag Use of substances for treating tumors
WO2003086461A2 (fr) * 2002-04-15 2003-10-23 Proteosys Ag Utilisation de substances pour traiter des tumeurs
WO2003086461A3 (fr) * 2002-04-15 2004-02-05 Proteosys Ag Utilisation de substances pour traiter des tumeurs
AU2003222293B2 (en) * 2002-04-15 2008-07-17 Proteosys Ag Use of substances for treating tumors
AU2003222293B8 (en) * 2002-04-15 2008-08-07 Proteosys Ag Use of substances for treating tumors
US7238513B2 (en) 2003-02-28 2007-07-03 University Of Utah Research Foundation Nucleic acid sequences encoding Conus protein disulfide isomerase
US8367362B2 (en) 2007-07-19 2013-02-05 Biomerieux Aminoacylase 1 assay method for the in vitro diagnosis of colorectal cancer
US9726670B2 (en) 2007-07-19 2017-08-08 Biomerieux Method for the assay of liver fatty acid binding protein, ACE and CA 19-9 for the in vitro diagnosis of colorectal cancer
US10591482B2 (en) 2007-07-19 2020-03-17 Biomerieux Method of assaying Apolipoprotein AI for the in vitro diagnosis of colorectal cancer
US8361731B2 (en) 2007-07-19 2013-01-29 Biomerieux Ezrin assay method for the in vitro diagnosis of colorectal cancer
US9890196B2 (en) 2007-07-19 2018-02-13 Biomerieux Ezrin assay method for the in vitro diagnosis of colorectal cancer
US9891223B2 (en) 2007-07-19 2018-02-13 Biomerieux Method of assaying leukocyte elastase inhibitor for the in vitro diagnosis of colorectal cancer
US8445211B2 (en) 2007-07-19 2013-05-21 Biomerieux I-Plastin assay method for the in vitro diagnosis of colorectal cancer
US8735078B2 (en) 2007-07-19 2014-05-27 Biomerieux Apolipoprotein AII assay method for the in vitro diagnosis of colorectal cancer
WO2010004214A1 (fr) * 2008-07-10 2010-01-14 bioMérieux Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
AU2009267844B2 (en) * 2008-07-10 2014-11-20 Biomerieux Protein disulfide isomerase assay method for the in vitro diagnosis of colorectal cancer
JP2016040258A (ja) * 2008-07-10 2016-03-24 ビオメリューＢｉｏｍｅｒｉｅｕｘ 結腸直腸癌のインビトロ診断のためのプロテインジスルフィドイソメラーゼ・アッセイ方法
US9388404B2 (en) 2008-07-10 2016-07-12 Biomerieux Protein disulfide isomerase assay method for the in vitro diagnosis of colorectal cancer
CN102089663B (zh) * 2008-07-10 2014-09-03 生物梅里埃公司 体外诊断结直肠癌的蛋白质二硫化物异构酶测定方法
US8367806B2 (en) 2008-07-10 2013-02-05 Biomerieux Protein disulfide isomerase assay method for the in vitro diagnosis of colorectal cancer
FR2933773A1 (fr) * 2008-07-10 2010-01-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
JP2011527429A (ja) * 2008-07-10 2011-10-27 ビオメリュー 結腸直腸癌のインビトロ診断のためのプロテインジスルフィドイソメラーゼ・アッセイ方法

Also Published As

Publication number Publication date
AU2001289864A1 (en) 2002-03-22
WO2002020731A3 (fr) 2002-07-25

Similar Documents

Publication Publication Date Title
US20020160394A1 (en) Regulation of transthyretin to treat obesity
WO2002020731A2 (fr) Regulation de l'enzyme humaine du type proteine disulfide isomerase
US20050214908A1 (en) Regulation of human transketolase-like enzyme
US20030171324A1 (en) Regulation of human desc1-like serine protease
US6593099B2 (en) Regulation of human S-acyl fatty acid synthase thioesterase-like enzyme
WO2002002755A2 (fr) Regulation d'enzyme de type thimet oligopeptidase humaine
US20040175815A1 (en) Regulation of human p78-like serube/threonine kinase
WO2002022631A2 (fr) Regulation d'une enzyme de type pyroglutamyl peptidase humaine
WO2002055712A2 (fr) Regulation de l'alanine aminotransferase humaine
WO2002032938A2 (fr) Regulation de la proteine humaine de type pgc-1
WO2002006455A2 (fr) Regulation de l'enzyme de type trypsine protease humaine des voies respiratoires
WO2002030969A2 (fr) Regulation une enzyme humaine de type carboxyesterase
WO2002006454A2 (fr) Regulation d'une enzyme humaine de type carboxylesterase
WO2002024884A2 (fr) Regulation de l'enzyme analogue a la serine palmitoyltransferase humaine
WO2001090318A2 (fr) Regulation de l'enzyme similaire a la polyamine oxydase humaine
US20030165973A1 (en) Regulation of human pgc-1-like protein
US20030049670A1 (en) Regulation of human leucine aminopeptidase-like enzyme
WO2001072955A2 (fr) Regulation de la proteine humaine apparentee a nedd1
WO2001073077A2 (fr) Regulation de serine racemase humaine
WO2003025162A2 (fr) Regulation du precurseur de la sous-unite alpha de prolyl 4-hydroxylase humaine
WO2003000725A2 (fr) Regulation de l'enzyme similaire a la ligase b lipoate-proteine humaine
WO2002024731A2 (fr) Regulation de proteine humaine de type fgd1
WO2001072798A2 (fr) Regulation de la proteine humaine apparentee a oatp2
WO2003035862A2 (fr) Regulation d'une proteine contenant une signature d'arginase humaine
WO2001072843A2 (fr) Regulation de genes humains lies a c-myb

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP